Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Gastroenterology · Gastric Neuroendocrine Tumor

The Diagnostic Puzzle: Essential Tests for Gastric NETs

At a Glance

Diagnosing a gastric neuroendocrine tumor (G-NET) requires specific tests to determine its type. A complete diagnosis relies on an endoscopic biopsy of both the tumor and the surrounding stomach lining, fasting gastrin blood tests, and advanced imaging like a DOTATATE PET/CT scan.

Getting an accurate diagnosis for a gastric neuroendocrine tumor (G-NET) is like solving a puzzle where several different pieces—blood work, imaging, and tissue samples—must fit together. Because G-NETs are classified into three distinct types with very different treatments, these tests are not just routine; they are the roadmap for your care [1][2].

The Essential “Two-Part” Biopsy

When your doctor performs an upper endoscopy (using a camera to look inside your stomach), it is standard to biopsy the tumor itself. However, in G-NETs, it is equally critical to biopsy the background mucosa—the normal-looking stomach lining away from the tumor [3][4].

  • Why it matters: Biopsying the background mucosa allows the pathologist to look for atrophic gastritis (a thinning of the stomach lining) or ECL cell hyperplasia (excessive growth of the cells that can turn into NETs) [4][5].
  • The Diagnosis: If the surrounding lining shows these changes, it strongly suggests a Type 1 G-NET, which is typically the least aggressive and most manageable form [3][6].

The Blood Work: Measuring Your Hormones

Blood tests help determine “why” the tumor grew by looking at the hormone environment in your body.

  • Fasting Serum Gastrin: Gastrin is a hormone that tells your stomach to make acid. In Type 1 and Type 2 G-NETs, gastrin levels are usually very high [7][3]. In the more aggressive Type 3, gastrin levels are typically normal [8].
  • Chromogranin A (CgA): This is a protein released by neuroendocrine cells. While historically used as a marker, many top NET specialists are moving away from routine CgA testing because it is notoriously unreliable. It can be easily elevated by common acid-blocking medications (PPIs) and other benign conditions, leading to false alarms [9].

Other Important Diagnostics: Stomach pH Testing

Sometimes, doctors measure the acidity of your stomach, which helps distinguish between the different types of G-NETs.

  • How it’s done: A pH test can be performed via a small probe placed during an endoscopy, or through a temporary capsule or catheter to measure acid over 24 hours.
  • What it means: A “high pH” (low acid) points to Type 1, while a “low pH” (high acid) can point to Type 2, which is associated with Zollinger-Ellison Syndrome [10][11].

Advanced Imaging: The DOTATATE Scan

While a standard CT or MRI can see larger masses, they often miss small neuroendocrine tumors. A specialized scan called a 68Gallium-DOTATATE PET/CT is now the gold standard for staging [12][13].

  • How it works: This scan uses a “radioactive tracer” that specifically sticks to somatostatin receptors—proteins found on the surface of most neuroendocrine cells [14].
  • Why use it: It is much more sensitive than traditional imaging at finding small lesions or identifying if the tumor has spread (metastasis) to other organs [13][15]. It can also help find a hidden primary tumor if the G-NET is actually a spread from somewhere else [16].

What Else Could It Be?

During an endoscopy, G-NETs can look like other, more common stomach growths. This is why the specific tests above are essential to rule out mimics like:

  • Gastrointestinal Stromal Tumors (GISTs): Another type of rare tumor that requires a different surgical approach [17].
  • Hyperplastic Polyps: Common, non-cancerous growths that can look similar to small G-NETs [18].
  • Adenocarcinoma: Standard stomach cancer, which requires much more aggressive treatment [5].

Common questions in this guide

Why does my doctor need to biopsy my normal stomach lining?
Biopsying the normal-looking background lining helps pathologists look for conditions like atrophic gastritis or ECL cell hyperplasia. Finding these changes strongly suggests a Type 1 gastric NET, which is usually the most manageable form of the disease.
Should I stop taking acid-blocking medication before my blood tests?
Yes, acid-blocking medications like proton pump inhibitors (PPIs) can falsely elevate your hormone levels and make specific blood tests unreliable. You should discuss with your doctor how long you need to stop these medications before your fasting gastrin test.
What does a high gastrin level mean for a gastric NET?
High levels of fasting serum gastrin are typically seen in Type 1 and Type 2 gastric neuroendocrine tumors. In contrast, the more aggressive Type 3 tumors usually present with normal gastrin levels.
Why is a DOTATATE scan recommended instead of a regular CT scan?
Standard CT or MRI scans often miss small neuroendocrine tumors. A DOTATATE PET/CT scan uses a specialized tracer that sticks to somatostatin receptors on the tumor cells, making it much better at detecting small lesions or cancer that has spread.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Did the biopsies include samples from the 'background mucosa' (the surrounding stomach lining) to look for atrophic gastritis?
  2. 2.Was my fasting serum gastrin test done while I was off proton pump inhibitors (PPIs), and what was the result?
  3. 3.Does the pathology report show evidence of 'ECL cell hyperplasia' in the non-tumor tissue?
  4. 4.Is a 68Gallium-DOTATATE PET/CT scan necessary at this stage to check for metastasis or a hidden primary gastrinoma?
  5. 5.How do these test results specifically determine if I have a Type 1, 2, or 3 tumor?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    A 15-year experience with gastric neuroendocrine tumors: Does type make a difference?

    Postlewait LM, Baptiste GG, Ethun CG, et al.

    Journal of surgical oncology 2016; (114(5)):576-580 doi:10.1002/jso.24369.

    PMID: 27393718
  2. 2

    GASTRIC NEUROENDOCRINE TUMOR: REVIEW AND UPDATE.

    Dias AR, Azevedo BC, Alban LBV, et al.

    Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery 2017; (30(2)):150-154 doi:10.1590/0102-6720201700020016.

    PMID: 29257854
  3. 3

    Unmasking the high-risk phenotype in autoimmune gastritis: A pathologist's roadmap for the clinician.

    Wang CL, Zeng M, Luo Y

    World journal of gastroenterology 2025; (31(48)):115244 doi:10.3748/wjg.v31.i48.115244.

    PMID: 41480315
  4. 4

    Gastric Neuroendocrine Tumors and Pernicious Anemia: A Case Report and Literature Review.

    Rudolph JJ, Agyei O, Telvizian T, Ghaneie A

    Cureus 2024; (16(11)):e73553 doi:10.7759/cureus.73553.

    PMID: 39669826
  5. 5

    The changing face of chronic autoimmune atrophic gastritis: an updated comprehensive perspective.

    Massironi S, Zilli A, Elvevi A, Invernizzi P

    Autoimmunity reviews 2019; (18(3)):215-222 doi:10.1016/j.autrev.2018.08.011.

    PMID: 30639639
  6. 6

    Case report: optimal tumor cytoreduction and octreotide with durable disease control in a patient with MEN-1 and Zollinger-Ellison syndrome-over a decade of follow-up.

    Daniels LM, Khalili M, Morano WF, et al.

    World journal of surgical oncology 2019; (17(1)):213 doi:10.1186/s12957-019-1758-6.

    PMID: 31818296
  7. 7

    Gastric Neuroendocrine Tumors (Carcinoids).

    Gluckman CR, Metz DC

    Current gastroenterology reports 2019; (21(4)):13 doi:10.1007/s11894-019-0684-7.

    PMID: 30868284
  8. 8

    Neuroendocrine Tumors of the Stomach.

    Corey B, Chen H

    The Surgical clinics of North America 2017; (97(2)):333-343 doi:10.1016/j.suc.2016.11.008.

    PMID: 28325190
  9. 9

    Predictors of Outcomes in Gastric Neuroendocrine Tumors: A Retrospective Cohort.

    Ortigão R, Afonso LP, Pimentel-Nunes P, et al.

    GE Portuguese journal of gastroenterology 2024; (31(4)):236-245 doi:10.1159/000530684.

    PMID: 39022301
  10. 10

    Gastrinoma in multiple endocrine neoplasia type 1 after total pancreatectomy: A case report.

    Gong S, Li Z, Liu XB, et al.

    Medicine 2019; (98(50)):e18275 doi:10.1097/MD.0000000000018275.

    PMID: 31852099
  11. 11

    Gastrinomas: Medical or Surgical Treatment.

    Norton JA, Foster DS, Ito T, Jensen RT

    Endocrinology and metabolism clinics of North America 2018; (47(3)):577-601 doi:10.1016/j.ecl.2018.04.009.

    PMID: 30098717
  12. 12

    Gallium-68-dotatate PET/CT is better than CT in the management of somatostatin expressing tumors: First experience in Africa.

    Lawal IO, Ololade KO, Lengana T, et al.

    Hellenic journal of nuclear medicine 2017; (20(2)):128-133 doi:10.1967/s002449910553.

    PMID: 28697189
  13. 13

    Diagnostic fficiency of 68Ga-DOTATATE PET/CT as ompared to 99mTc-Octreotide SPECT/CT andonventional orphologic odalities in euroendocrine umors.

    Fallahi B, Manafi-Farid R, Eftekhari M, et al.

    Asia Oceania journal of nuclear medicine & biology 2019; (7(2)):129-140 doi:10.22038/AOJNMB.2019.39392.1263.

    PMID: 31380452
  14. 14

    Gastroenteropancreatic Neuroendocrine Tumor Diagnosis: DOTATATE PET/CT.

    Kandathil A, Subramaniam RM

    PET clinics 2023; (18(2)):189-200 doi:10.1016/j.cpet.2022.11.001.

    PMID: 36585339
  15. 15

    Most of the Intended Management Changes After 68Ga-DOTATATE PET/CT Are Implemented.

    Calais J, Czernin J, Eiber M, et al.

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2017; (58(11)):1793-1796 doi:10.2967/jnumed.117.192450.

    PMID: 28473600
  16. 16

    Gastrinoma and Zollinger Ellison syndrome: A roadmap for the management between new and old therapies.

    Rossi RE, Elvevi A, Citterio D, et al.

    World journal of gastroenterology 2021; (27(35)):5890-5907 doi:10.3748/wjg.v27.i35.5890.

    PMID: 34629807
  17. 17

    Gastric Neuroendocrine Tumor Mimicking Gastrointestinal Stromal Tumor: A Case Report.

    Lee J, Oh SJ

    Case reports in oncology 2021; (14(3)):1271-1276 doi:10.1159/000518078.

    PMID: 34720927
  18. 18

    A case of gastric neuroendocrine tumor with an unusual morphology.

    Ohashi T, Okimoto K, Matsusaka K, et al.

    Clinical journal of gastroenterology 2026; (19(2)):446-450 doi:10.1007/s12328-026-02289-1.

    PMID: 41697540

This page provides educational information about diagnostic testing for gastric neuroendocrine tumors (G-NETs). It does not replace professional medical advice. Always consult your gastroenterologist or oncologist regarding your specific test results and diagnosis.

Get notified when new evidence is published on Neuroendocrine tumor of stomach.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.